{"nct_id":"NCT03440736","title":"Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome","status":"COMPLETED","status_verified_date":"2023-05","start_date":"2018-02-28","start_date_type":"ACTUAL","primary_completion_date":"2021-11-30","primary_completion_date_type":"ACTUAL","completion_date":"2022-06-03","completion_date_type":"ACTUAL","phases":["PHASE4"],"tickers":["NVS"]}